New Delhi: Pharmaceutical firm Suven Life Sciences on Monday said it has received two patents in the US for its two chemical entities used in treatment of neurodegenerative diseases like Parkinson and Schizophrenia.
The US Patent Office has issued two patents corresponding to two new chemical entities for the treatment of disorders associated with neurodegenerative diseases, Suven Life said in a statement.
“We are very pleased by the grant of these patents to Suven by US Patent office for our pipeline of molecules in CNS arena that are being developed for cognitive disorders, which has an estimated $20 billion market potential globally,” Suven CEO Venkat Jasti said.
Products out of these inventions may be out-licensed at various phases of clinical development, the company said.
With these new patents, Suven has total of four granted US patents on new chemical entities, it added.
Shares of Suven rose by 5% to hit its upper trading limit of Rs31.55 on the Bombay Stock Exchange.